You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202301 - 202310 of 207712 results
  1. Rapid diagnostic to determine CMV serological status

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    The goal of this project is to develop a diagnostic that can support the enrollment of seronegative individuals in clinical trials of candidate cytomegalovirusCMVvaccinesCongenital CMV infection is one of the leading causes of non genetic birth defects worldwideIf a successful vaccine can be brought to marketit will have a significant impact on the number of babies born with hearing and vision los ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Aptamer Affinity Reagents to Immune Targets in Non-human Disease Models

    SBC: BASE PAIR BIOTECHNOLOGIES INC            Topic: NIAID

    This goal of this program is to address the limited availability of reagentsantibodiesproteinsligandsfor the identification and discrimination of immune cells and the characterization of immune responses in nonmammalian models and mammalian models for which immunologic reagents are limitede gguinea pigferretcotton ratFor examplethe progression of disease that follows infection of guinea pigs with ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. EAP-Derived Monoclonal Antibodies or Phenotyping Immune Cells of Animal Models of Disease

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: NIAID

    The investigation of mechanismspotential treatmentsand vaccines for infectious diseases relies on animal models that can be infected by the same agent as humans and display similar symptomsIn many casessuch animals are not the typicalwell characterized research modelsbut rather non traditional speciesOne example of this situation is the ferret model of influenzaA major drawback of non traditional ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A Smartphone-based point-of-care Sensor for Rapid and Sensitive Detection of Malaria in Low-Resource Applications

    SBC: GINER INC            Topic: NIAID

    The wide availability of rapidfield portablelow costand sensitive molecular diagnostic for point of care detection of malaria parasites would have a significant benefit for intervention programs aimed at eliminating malaria in affected populationsMalaria remains one of the most serious infectious diseases in low income countriesthreatening nearly half of the world s population and causing an estim ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Sample Sparring Assay for Isolation and Analysis of Immune Cell Populations using Magnetic Ratcheting

    SBC: FERROLOGIX INC            Topic: NIAID

    Immunoassays which minimize sample usage are a critical need to develop personalized therapeutics like immunotherapy and precision immunomodulatory devicesThis often involves the isolation and analysis of specific cell types from blood or tissue samplesUnfortunatelythe current workflows needed to isolate these cell populations utilize magnetic cell sorting and or flow cytometry which are expensive ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Toward the Development of a Protein: Non-protein Macromolecular Adjuvants

    SBC: Hafion Inc.            Topic: NIAID

    An existing problem being faced in the development of new vaccines is the need for targeting bacterial infections that occur at mucosal sites such as the upper airway and the gastrointestinal tractOvercoming this problem will require the use of novel vaccine formulations andin particularthe use of novel immune enhancing agentsadjuvantsthat promote immune responses that are effective at mucosal sit ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Nanvas TM (Oil in Water Nanoemulsion Adjuvant) Formulated Allergens as Intranasal Immunotherapeutic Vaccines for Peanut Allergy

    SBC: BLUEWILLOW BIOLOGICS INC            Topic: NIAID

    Food allergy is an emerging health problem with increasing incidence and severityparticularly in childrenand continuing throughout adulthoodSincethe incidence of self reported peanut allergy has risen significantly representing a mounting financial burden to the healthcare systemWith no approved therapeutics availablevarious forms of immunotherapy have been evaluated but generally do not facilitat ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Rational Development of a Combination Nanoparticle Adjuvant for Influenza

    SBC: HDT BIO CORP            Topic: NIAID

    SignificanceHighly pathogenic avian H Ninfluenzawhich has killedpeople sinceis poised to cause a pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccines are insufficiently immunogenic without the addition of adjuvantsbut responses to these adjuvanted vaccines are not durable and may not be protective against newly emergent viral strainsProposed solutionWe have develop ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Nano-emulsion Immuno-suppressive Adjuvant for Allergy Vaccines

    SBC: EPITOGENESIS INC            Topic: NIAID

    Bronchial asthma is a chronic respiratory disease that can be lethalAsthma is a global health problemAccording to the CDCin USAthere are currentlymillion asthma sufferers and this number is increasingHalf of the asthma patients have at least one hospitalization per yearwith an annual medical cost of $BTraditionallyasthma is treated during flare ups with prescribed inhaled corticosteriodsIn recent ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Discovery of Parasite-Derived Tolerogenic Adjuvants

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    Our goal is to identify novel parasite derived immunomodulatory tolerogenic adjuvants that can suppress pro inflammatory and autoimmune disease statessuch as typediabeteswhich has no disease modifying treatmentParasitic helminths establish chronic infection by modulating host innate and adaptive immune responsesdown regulating T effector cellsstimulating Thand or inducing regulatory B and T cellsS ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government